IGF1, insulin like growth factor 1, 3479

N. diseases: 1206; N. variants: 36
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 AlteredExpression disease BEFREE While current treatment modalities have greatly improved prognoses for most patients, a significant number present clinical symptoms of acromegaly with elevated levels of IGF-1 in the absence of increased GH levels, a phenomenon known as micromegaly. 31071497 2020
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE A univariate analysis was conducted and eight features, including age, hypertension, ophthalmic disorders, GH, IGF-1, nadir GH, maximal tumor diameter, and Knosp grade, were significantly associated with the TSS response in patients with acromegaly. 31673954 2020
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE Achieving biochemical control (normalization of insulin-like growth factor-1 [IGF-1] and growth hormone [GH]) is a key goal in acromegaly management. 31741320 2020
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 GeneticVariation disease BEFREE The mean age of the 30 acromegaly patients (M/F:14/16) was 47.26 ± 12.52 years (range: 18-64 years) and that of the healthy volunteers (M/F: 17/13) was 44.56 ± 10.74 years (range: 19-62 years).Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels were measured using an electrochemiluminescence method, and serum sclerostin levels using an enzyme-linked immunosorbent assay.The Mann-Whitney U test was used to compare sclerostin levels between the two groups. 31821453 2020
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 AlteredExpression disease BEFREE The paradoxical GH response reflected the clinical characteristics, especially IGF-I level, glucose metabolism, and drug efficacy in acromegaly. 30476255 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 GeneticVariation disease BEFREE One hundred acromegaly patients on medical therapy (mean age = 47.1 years; SD = 11.96) completed an online preference study evaluating hypothetical patient profiles described in terms of insulin-like growth factor-I (IGF-I) levels, tumor size, comorbid conditions, signs/symptoms, and quality of life (QoL). 30627944 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE Background Biochemical control of GH/IGF-I excess in acromegaly (ACRO) is associated with persistent impairment of trabecular microstructure leading to increased risk of vertebral fractures. 30640713 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 GeneticVariation disease BEFREE Therefore, routine screening of GD should be considered in women with acromegaly, particularly in those with risk factors for GD and with uncontrolled IGF-1 levels before pregnancy. 31520541 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE Acromegaly is characterized by an excess of growth hormone (GH) and insulin like growth-factor 1 (IGF1). 31751301 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE We will focus on the issues regarding the measurement and interpretation of IGF-I concentrations in the management of acromegaly patients. 30311754 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 AlteredExpression disease BEFREE Incidence of mortality, its correlation with GH (cumulative exposure vs last value), and IGF-I levels and the shift in the main cause of mortality in patients with acromegaly are also addressed. 30184064 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 GeneticVariation disease BEFREE Suppressor of cytokine signaling (SOCS) 2, a negative regulator of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), which is associated with acromegaly and cancers, is a promising candidate molecule for treating various diseases. 30343638 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE Insulin-like growth factor 1 (IGF-1) assay should be used as a screening test whenever acromegaly is suspected. 30843181 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 AlteredExpression disease BEFREE Between PTC group without acromegaly and APTC, galectin 3 and IGF1 expression was significantly higher in acromegalic patients (p<0.01 for all) while RAS was predominantly higher in PTC patients without acromegaly (p<0.01). 29890543 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 AlteredExpression disease BEFREE The participants of the study were divided into 3 groups as the control (Group-I), acromegaly patients with remission (Group-II), and acromegaly patients without remission (Group-III).Insulin growth factor-1 (IGF-1) level significantly increased from Group-I to Group-III. 30653179 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE Acromegaly is associated with clinically high IGF-I concentrations. 31755099 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 AlteredExpression disease BEFREE Treatments used to normalize IGF-I levels in patients with acromegaly could have differential effects on cardiovascular risk factors and metabolic parameters. 30397873 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. 30843342 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE The GH-receptor antagonist pegvisomant (PEG) reduces peripheral IGF-1 synthesis and is used to treat acromegaly patients resistant or intolerant to somatostatin analogues (SSA). 30772778 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE We studied 23 patients with active acromegaly before and for ≤2 years after surgical (n = 13) or GH receptor antagonist therapy with pegvisomant (n = 10), and 100 healthy subjects with morning fasting blood samples for AgRP, leptin, GH, and IGF-1 and anthropometric measurements. 31361303 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 AlteredExpression disease BEFREE We measured serum levels of GH, IGF-1, sDlk1 and sKlotho (both by ELISA) in 42 treatment-naïve acromegaly patients (20 females/22 males) before and 1-3 months after transsphenoidal surgery. 30818110 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE Acromegaly is known to be associated with high incidence of malignancies probably due to the mitogenic effects of IGF-1. 31185505 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 AlteredExpression disease BEFREE Recent studies have shown that increased life expectancy in acromegaly patients who attain normal GH and IGF-I levels is associated with more deaths due to age-related cancers. 30500870 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 Biomarker disease BEFREE No significant correlation was found between IGF-1 ULN and QoL scores in acromegaly. 30548674 2019
CUI: C0001206
Disease: Acromegaly
Acromegaly
0.400 GeneticVariation disease BEFREE In conclusion, the pathophysiology of endothelial dysfunction in the condition of GH and IGF-1 excess remains a crucial area of investigation to fully dissect the association of acromegaly with cardiovascular disease complications. 31396153 2019